IL17A and relapsing-remitting multiple sclerosis: (2021) showed the inhibitory effect of fluoxetine on IL-17, IFN-γ, and GM-CSF production by anti-CD3/CD28-activated CD4+ T-cells in patients with relapsing-remitting MS and healthy subjects (18), which confirms the anti-inflammatory effect of fluoxetine on Th17-cells in MS (49).